Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 6/20 | 0.77 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.77 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.77 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.77 |
| ▸ | PRKCI | P41743 | 2/20 | 0.52 |
| ▸ | ATR | Q13535 | 10/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1310581 | 0.87 | PIK3CD (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGPRKCI | |
| SCHEMBL10276769 | 0.80 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1310080 | 0.79 | PIK3CA (0.76) | PIK3CAPIK3CDPIK3CBPIK3CGPRKCI | |
| SCHEMBL1311652 | 0.76 | PIK3CA (0.74) | PIK3CAPIK3CDPIK3CBPIK3CGPRKCI | |
| SCHEMBL1164956 | 0.76 | PIK3CA (0.71) | PIK3CAPIK3CDPIK3CBPIK3CGPRKCI | |
| SCHEMBL15374745 | 0.74 | PIK3CA (0.78) | PIK3CAPIK3CDPIK3CBPIK3CGPRKCI | |
| SCHEMBL10092302 | 0.74 | PIK3CA (0.78) | PIK3CAPIK3CDPIK3CBPIK3CGPRKCI | |
| SCHEMBL1309467 | 0.74 | PIK3CD (0.75) | PIK3CAPIK3CDPIK3CBPIK3CGATR | |
| SCHEMBL18552481 | 0.71 | PIK3CD (0.72) | PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL2674252 | 0.71 | PIK3CD (0.75) | PIK3CAPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190040079-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2019-02-07 | — | — | US | disclosed |
| US-9938290-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-9938290-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-20180009826-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2018-01-11 | — | — | US | disclosed |
| US-9580442-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2017-02-28 | — | — | US | disclosed |
| US-9580442-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2017-02-28 | — | — | US | disclosed |
| US-20160108057-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2016-04-21 | — | — | US | disclosed |
| US-20160108057-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2016-04-21 | — | — | US | disclosed |
| US-9200007-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2015-12-01 | — | — | US | disclosed |
| US-9200007-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2015-12-01 | — | — | US | disclosed |
| EP-2467387-B1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS. | KARUS THERAPEUTICS LTD (GB) | 2015-01-07 | — | — | EP | disclosed |
| US-20120178737-A1 | Tricyclic Heterocyclic Compounds as Phosphoinositide 3-Kinase Inhibitors | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2012-07-12 | — | — | US | disclosed |
| US-20120178737-A1 | Tricyclic Heterocyclic Compounds as Phosphoinositide 3-Kinase Inhibitors | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2012-07-12 | — | — | US | disclosed |
| EP-2467387-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | Karus Therapeutics Limited (GB) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011021038-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009826-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PIK3CA, PIK3CD, PIK3C2A | PIK3CA 1/4885PIK3CD 2/4885PIK3CB 11/4885 |
| US-20120178737-A1 | Tricyclic Heterocyclic Compounds as Phosphoinositide 3-Kinase Inhibitors | PIK3CA, PIK3CD, PIK3C2A | PIK3CA 1/4885PIK3CD 2/4885PIK3CB 11/4885 |
| US-20190040079-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PIK3CA, PIK3CD, PIK3R2 | PIK3CA 1/4885PIK3CD 2/4885PIK3CB 11/4885 |
| US-20160108057-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PIK3R2, PIK3R1, PIK3CA | PIK3CA 3/4885PIK3CD 4/4885PIK3CB 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.